Tharimmune (THAR) director reports 90,000 options at $3.075
Tharimmune (THAR) reported insider activity on a Form 4.
Rhea-AI Filing Summary
Tharimmune (THAR) reported insider activity on a Form 4. A company director reported acquiring 90,000 stock options on 11/03/2025 at an exercise price of $3.075 per share. The options are first exercisable on 11/03/2025 and expire on 11/03/2035.
Following the transaction, the filing lists 190,000 derivative securities beneficially owned. The ownership is marked as Indirect (I), with a footnote referencing relationships among Gravitas Capital LP, Gravitas Capital Partners LLC, and Vincent S. LoPriore. This filing records the insider’s equity-linked position and timing terms.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option | 90,000 | $0.00 | $0.00 |
Footnotes (1)
- F1. Gravitas Capital LP is a Delaware limited partnership whose sole general partner is Gravitas Capital Partners LLC. The managing member of Gravitas Partners LLC is Vincent S. LoPriore. As a result, Gravitas Capital LP is deemed to be the indirect owner of the securities held directly by Vincent S. LoPriore. Despite such shared beneficial ownership, the reporting persons disclaim that they constitute a statutory group within the meaning of Rule 13d-5(b) (1) of the Securities Exchange Act of 1934
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Tharimmune (THAR) disclose in this Form 4?
What is the exercise price and term of the THAR options?
How many derivative securities are held after the transaction?
Is the ownership direct or indirect in this THAR Form 4?
Did the Form 4 indicate a sale of Tharimmune common stock?
Who signed the THAR Form 4 filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.